AR124558A1 - Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco - Google Patents
Anticuerpos anti-cd228 y conjugados de anticuerpo-fármacoInfo
- Publication number
- AR124558A1 AR124558A1 ARP210102172A ARP210102172A AR124558A1 AR 124558 A1 AR124558 A1 AR 124558A1 AR P210102172 A ARP210102172 A AR P210102172A AR P210102172 A ARP210102172 A AR P210102172A AR 124558 A1 AR124558 A1 AR 124558A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- amino acid
- seq
- acid sequence
- antibody
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan nuevos anticuerpos anti-CD228 y conjugados de anticuerpo-fármaco y métodos para usar tales anticuerpos anti-CD228 y conjugados de anticuerpo-fármaco para tratar el cáncer. Reivindicación 1: Un anticuerpo anti-CD228 aislado, o un fragmento de unión a antígeno del mismo, que comprende una región variable de cadena pesada y una región variable de cadena ligera, donde la región variable de cadena pesada comprende: (i) una CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 1; (ii) una CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 2; y (iii) una CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 3; y en donde la región variable de cadena ligera comprende: (i) una CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 4; (ii) una CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 5; y (iii) una CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 6, en donde al menos un residuo de histidina en una CDR de cadena ligera está sustituido con un aminoácido diferente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063061111P | 2020-08-04 | 2020-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124558A1 true AR124558A1 (es) | 2023-04-12 |
Family
ID=77519784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102172A AR124558A1 (es) | 2020-08-04 | 2021-08-04 | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230295330A1 (es) |
EP (1) | EP4192871A1 (es) |
JP (1) | JP2023537714A (es) |
KR (1) | KR20230042518A (es) |
CN (1) | CN116568337A (es) |
AR (1) | AR124558A1 (es) |
AU (1) | AU2021320739A1 (es) |
CA (1) | CA3189225A1 (es) |
IL (1) | IL300176A (es) |
MX (1) | MX2023001143A (es) |
TW (1) | TW202221034A (es) |
WO (1) | WO2022031652A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023231877A1 (zh) * | 2022-05-31 | 2023-12-07 | 山东博安生物技术股份有限公司 | 抗cd228抗体及其药物偶联物 |
WO2024064714A2 (en) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Antibodies that bind cd228 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004050867A1 (en) * | 2002-12-02 | 2004-06-17 | Seattle Genetics, Inc. | MODIFIED L49-sFv EXHIBITING INCREASED STABILITY AND METHODS OF USE THEREOF |
BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
EP2722051B1 (en) | 2005-07-07 | 2018-11-07 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
LT2825036T (lt) * | 2012-03-16 | 2018-07-10 | Regeneron Pharmaceuticals, Inc. | Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti graužikai, išvesti ju gamybai |
TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
-
2021
- 2021-08-03 CA CA3189225A patent/CA3189225A1/en active Pending
- 2021-08-03 MX MX2023001143A patent/MX2023001143A/es unknown
- 2021-08-03 US US18/018,504 patent/US20230295330A1/en active Pending
- 2021-08-03 CN CN202180056942.XA patent/CN116568337A/zh active Pending
- 2021-08-03 TW TW110128583A patent/TW202221034A/zh unknown
- 2021-08-03 AU AU2021320739A patent/AU2021320739A1/en active Pending
- 2021-08-03 KR KR1020237007681A patent/KR20230042518A/ko unknown
- 2021-08-03 JP JP2023507592A patent/JP2023537714A/ja active Pending
- 2021-08-03 EP EP21762211.7A patent/EP4192871A1/en active Pending
- 2021-08-03 IL IL300176A patent/IL300176A/en unknown
- 2021-08-03 WO PCT/US2021/044273 patent/WO2022031652A1/en active Application Filing
- 2021-08-04 AR ARP210102172A patent/AR124558A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021320739A1 (en) | 2023-02-23 |
JP2023537714A (ja) | 2023-09-05 |
WO2022031652A1 (en) | 2022-02-10 |
MX2023001143A (es) | 2023-02-22 |
TW202221034A (zh) | 2022-06-01 |
CN116568337A (zh) | 2023-08-08 |
EP4192871A1 (en) | 2023-06-14 |
US20230295330A1 (en) | 2023-09-21 |
CA3189225A1 (en) | 2022-02-10 |
KR20230042518A (ko) | 2023-03-28 |
IL300176A (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
PE20211709A1 (es) | Anticuerpos que reconocen tau | |
AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
NZ585559A (en) | Humanized antibodies against tl1a | |
PE20040947A1 (es) | MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA | |
AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
CU20210073A7 (es) | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs | |
PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
PE20221869A1 (es) | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap | |
AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
RU2018106456A (ru) | Антитело к epha4 | |
PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
AR079217A1 (es) | Composiciones y metodos para el diagnostico y el tratamiento de tumores | |
PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
AR115192A1 (es) | Anticuerpos | |
PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
RU2021128024A (ru) | Способы культивирования клеток | |
AR120430A1 (es) | Células car-t dirigidas a epha3 para el tratamiento de tumores | |
AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
CA2538725A1 (en) | Nogo-a binding molecules and pharmaceutical use thereof |